



BioMed Research International

Special Issue on  
**Immunotherapy of Hepatocellular Carcinoma:  
Overcoming the Challenges**

# CALL FOR PAPERS

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide, and current therapies have offered only marginal survival benefits at the cost of undesirable side effects. In recent years, great progress has been made in the field of immunotherapy, a promising strategy in which the body's own immune system is harnessed to fight against cancer. Although immunotherapy has the potential to offer safe, systemic, and long-lasting tumor responses, the inherent tolerogenic microenvironment in the liver imposes unique challenges, which must be addressed in order to fully exploit the benefits of immune-based therapies. New research on the mechanisms of immune escape of HCC, as well as the development of novel strategies to break immune tolerance, such as immune checkpoint inhibition, oncolytic virus-based therapies, vaccine approaches, and combination therapies, makes this an exciting time for translational research as improved therapies for HCC begin to make their way into clinical practice.

We invite investigators to submit original research articles, as well as review articles, that will stimulate the scientific community and enhance the growing body of knowledge on immunotherapy of HCC. We are interested in both preclinical and clinical data on immune-based therapies for HCC, as well as key interactions of the local tumor microenvironment which influence therapeutic outcomes.

Potential topics include, but are not limited to:

- ▶ Mechanisms of immune escape
- ▶ Unique features of the HCC microenvironment (in both a healthy and diseased liver setting) that impact the efficacy of immune-based therapies
- ▶ Oncolytic virus-based immunotherapies
- ▶ Immune checkpoint inhibition
- ▶ Tumor-associated antigens in HCC
- ▶ Adoptive immune cell therapies and vaccine approaches
- ▶ Preclinical animal models of HCC for studying immunotherapy
- ▶ Clinical trials involving immunotherapy for HCC

Authors can submit their manuscripts via the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/bmri/hepatology/ihco/>.

**Lead Guest Editor**

Jennifer Altomonte, Technische Universität München, Munich, Germany  
[jennifer.altomonte@lrz.tum.de](mailto:jennifer.altomonte@lrz.tum.de)

**Guest Editors**

Sophie Conchon, University of Nantes, Nantes, France  
[sophie.conchon@univ-nantes.fr](mailto:sophie.conchon@univ-nantes.fr)

Guillermo Mazzolini, Austral University, Buenos Aires, Argentina  
[gmazzoli@cas.austral.edu.ar](mailto:gmazzoli@cas.austral.edu.ar)

**Manuscript Due**

Friday, 18 March 2016

**First Round of Reviews**

Friday, 10 June 2016

**Publication Date**

Friday, 5 August 2016